The dietary supplement industry sometimes relies on eye-catching numbers to signal potency and value. But as the National Advertising Division’s (NAD) recent decision in Case No. 7522, Reus Research LLC v. Iron Rock Ventures LLC, makes clear, a big number on the front label must be properly supported, and a fine-print disclaimer buried in the Supplement Facts Panel cannot save a misleading claim.
The Advertising Claims
Iron Rock Ventures LLC (Iron Rock) markets the thinbi NAD+ dietary supplement, a product containing NAD+ (nicotinamide adenine dinucleotide) along with several botanical extracts. The front label of the thinbi NAD+ product prominently displays the statement “8,457MG | 30 CAPSULES.” The same figure appeared in Amazon product page headlines (e.g., “NAD Supplement 8,457 mg Extra Strength…”) and in Instagram posts featuring the product.
The back-label Supplement Facts Panel (SFP), however, stated that each two-capsule serving contains 300 mg of NAD+ and three botanical extracts at 100 mg each, totaling only 379 mg of active dietary ingredients per capsule. The SFP included equivalency statements for those extracts — “Equivalent to 2,000 mg of Green Tea Leaf,” “Equivalent to 1,000 mg of Turmeric Root,” and “Equivalent to 5,000 mg of Grape Seed” — and these figures, when added together with the NAD+ amount, produce the headline “8,457MG” number.
Reus Research LLC (Reus), a competing supplement maker, challenged both the express dosage claim and the equivalency statements, arguing that Iron Rock conveyed the false message that the product contains 8,457 mg of active dietary ingredients per capsule.
NAD’s Analysis
8,457 mg Claim: NAD found that a reasonable consumer would interpret the prominently displayed “8,457MG” (both on the front label and in Amazon headlines) as representing the actual amount of active ingredients in a capsule. Iron Rock argued that consumers would not read the number literally and would turn to the Supplement Facts Panel for accurate quantitative information. NAD rejected this argument, reaffirming a key principle that information in a Supplement Facts Panel cannot effectively qualify an express claim when it contradicts that claim. In other words, disclosures are tools for limiting or clarifying advertising messages, not for correcting false or misleading ones.
Equivalency Claims: NAD also scrutinized the three “equivalent to” statements for the botanical extracts. While NAD does not have jurisdiction over claims appearing solely in the SFP on product packaging (which is a regulatory disclosure, not national advertising), it does have jurisdiction over those same claims when they are republished on platforms as advertising (like Amazon). There, NAD found that the equivalency statements lacked adequate support. An article that Iron Rock submitted explained that herb-to-extract ratios reflect only how much raw plant material is used in manufacturing. They do not indicate that an extract is therapeutically equivalent to the whole plant. FDA draft guidance similarly cautions that extraction can materially alter a botanical’s composition, potentially creating an entirely new dietary ingredient. Based on this record, NAD concluded that Iron Rock’s equivalency claims were unsubstantiated.
The NAD+ (nicotinamide adenine dinucleotide) Content Claims: On the separate question of whether the “8,457MG” statement implied the product contained 8,457 mg of NAD+ (nicotinamide adenine dinucleotide) specifically, NAD reached a more nuanced conclusion. Because the front label and Amazon headlines reference multiple ingredients alongside the figure, a reasonable consumer would be unlikely to conclude that the entire 8,457 mg consists of NAD+. However, the Instagram posts, which featured an earlier label version displaying “NAD+ Complex” next to the prominent number, presented a closer call. NAD found that, in that short-form social media context, some consumers could reasonably interpret the figure as representing the amount of NAD+ in the product. Since the product contains only 150 mg of NAD+ per capsule, NAD recommended modification of those claims as well.
Referral by NAD: Because Iron Rock declined to submit an Advertiser’s Statement (meaning it did not commit to comply with NAD’s recommendations in writing), NAD referred the matter to the appropriate regulatory authorities (including state attorneys general and the advertising platforms where the claims appeared).
Lessons for Advertisers
This decision offers several important reminders for dietary supplement marketers:
- A prominent number on the front label is an express claim. NAD will evaluate what a reasonable consumer would understand from them, regardless of what explanatory information appears in smaller type elsewhere on the packaging or in a technical disclosure panel.
- The Supplement Facts Panel cannot rescue a misleading front-label claim. The SFP is a regulatory requirement, not a commercial correction device. Advertisers cannot make a misleading express claim on the front label and then rely on back-panel disclosures to cure the problem. If the SFP contradicts an express claim rather than simply limiting or clarifying it, the express claim should not be made.
- Industry practice is not a defense. Iron Rock argued that its advertising was consistent with how other companies in the nutraceutical space present botanical extract information. NAD was not persuaded. The fact that an advertising practice is common in an industry does not make it accurate or substantiated.
- The science needs to support the claim. Iron Rock submitted a trade publication article discussing botanical extracts that ultimately undermined its own equivalency claims by explaining that extract ratios do not establish therapeutic equivalence. Before submitting substantiation to NAD, advertisers should ensure that their evidence does what they say it does.
- Context matters for implied claims, especially on social media. NAD’s analysis of the Instagram posts serves as a reminder that short-form social media content can change how consumers interpret advertising. When a close-up product image is the centerpiece of a post, the headline number may convey a very different message than it would in a more information-rich environment such as the retailer’s website. Advertisers should evaluate their claims as consumers will encounter them across every channel.
- Engage with NAD. When an advertiser declines to participate in the NAD process or refuses to provide an Advertiser’s Statement, NAD refers the matter to government agencies and relevant advertising platforms. That outcome can be far more consequential than working cooperatively with NAD in the first instance.
The decision is a useful reminder that the dietary supplement space remains an area of active NAD scrutiny, particularly for claims that use impressive sounding numbers or scientific sounding equivalencies to signal potency. Advertisers should carefully evaluate whether their front-label claims accurately reflect the actual composition of their products, and whether their substantiation genuinely supports every message a reasonable consumer might take away.
The material contained in this communication is informational, general in nature and does not constitute legal advice. The material contained in this communication should not be relied upon or used without consulting a lawyer to consider your specific circumstances. This communication was published on the date specified and may not include any changes in the topics, laws, rules or regulations covered. Receipt of this communication does not establish an attorney-client relationship. In some jurisdictions, this communication may be considered attorney advertising.
